Impact of KIT Exon 10 M541L Allelic Variant on the Response to Imatinib in Aggressive Fibromatosis: Analysis of the Desminib Series by Competitive Allele Specific Taqman PCR Technology

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Sep 2

PMID 25174682

Citations 10

Authors

Armelle Dufresne

Laurent Alberti

Mehdi Brahmi

Sarah Kabani

Heloise Philippon

David Perol

Jean Yves Blay

Affiliations

Soon will be listed here.

Abstract

Background: Aggressive fibromatosis (AF) is a rare fibroblastic proliferative disease with a locally aggressive behavior and no distant metastasis, characterized by driver mutations in CTNNB1 or the APC gene. When progressive and/or symptomatic AF is not amenable to local management, a variety of medical treatments may be efficient, including imatinib mesylate. The phase II "Desminib trial" included 40 patients with AF to evaluate the toxicity and efficacy of imatinib resulting in a 65% tumor control rate at 1 year. We investigated a potential predictive value of KIT exon 10 M541L variant (KITL541) on this prospective series.

Methods: DNA was extracted in sufficient quantity from 33 patients included in the Desminib trial. The detection of KITL541 was performed by Competitive Allele-Specific Taqman® PCR technology. Chi-2 analyses were performed to search for a correlation between KIT status and tumor response. Progression free (PFS) and overall survival (OS) were compared by log-rank test after Kaplan-Meier analysis.

Results: In 6 out of 33 cases (18%), the technique failed to determine the mutational status; 5 patients (19%) harboured KITL541 and 22 patients (81%) were classified as KIT wild type. Compared with total cohort, KITL541 frequency did not distinguish between different clinical characteristics. In the KITL541 and the KITWT subgroups, the tumor control rate at 1 year was 100% and 68%, respectively (p = 0.316). The median PFS of patients harboring KITL541 or not is 29.9 and 24.5 months, respectively (p = 0.616), and the median OS is not reached, in any of the groups.

Conclusion: Our results do not support a predictive effect of KITL541 on the efficacy of imatinib for patients with AF.

Citing Articles

Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in , , , and in 30% of Thymic Carcinomas.

Szpechcinski A, Szolkowska M, Winiarski S, Lechowicz U, Wisniewski P, Knetki-Wroblewska M Cancers (Basel). 2022; 14(14).

PMID: 35884448 PMC: 9324890. DOI: 10.3390/cancers14143388.

The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas.

Zaman N, Dass S, Du Parcq P, MacMahon S, Gallagher L, Thompson L Cancer Genomics Proteomics. 2020; 17(6):715-727.

PMID: 33099473 PMC: 7675657. DOI: 10.21873/cgp.20226.

Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases.

Trautmann M, Rehkamper J, Gevensleben H, Becker J, Wardelmann E, Hartmann W Sci Rep. 2020; 10(1):3368.

PMID: 32099073 PMC: 7042250. DOI: 10.1038/s41598-020-60237-6.

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Arend R, Londono A, Montgomery A, Smith H, Dobbin Z, Katre A Mol Cancer Res. 2018; 16(5):813-824.

PMID: 29523763 PMC: 6497146. DOI: 10.1158/1541-7786.MCR-17-0594.

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.

Hu W, Yang Y, Zhang L, Yin J, Huang J, Huang L Cancer Med. 2017; 6(5):962-974.

PMID: 28382702 PMC: 5430107. DOI: 10.1002/cam4.980.

References

Penel N, Le Cesne A, Bui B, Perol D, Brain E, Ray-Coquard I . Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2010; 22(2):452-7. DOI: 10.1093/annonc/mdq341. View

Kurtz J, Asmane I, Voegeli A, Neuville A, Dufresne A, Litique V . A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis. Sarcoma. 2010; 2010:458156. PMC: 2841250. DOI: 10.1155/2010/458156. View

Foster R, Byrnes E, Meldrum C, Griffith R, Ross G, Upjohn E . Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol. 2008; 159(5):1160-9. DOI: 10.1111/j.1365-2133.2008.08827.x. View

Bonvalot S, Desai A, Coppola S, Le Pechoux C, Terrier P, Domont J . The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol. 2012; 23 Suppl 10:x158-66. DOI: 10.1093/annonc/mds298. View

Rocha J, Luz Duarte M, Marques H, Torres F, Tavares P, Silva A . Association of adult mastocytosis with M541L in the transmembrane domain of KIT. J Eur Acad Dermatol Venereol. 2010; 24(9):1118-9. DOI: 10.1111/j.1468-3083.2010.03599.x. View

von Mehren M, Benjamin R, Bui M, Casper E, Conrad 3rd E, DeLaney T . Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10(8):951-60. DOI: 10.6004/jnccn.2012.0099. View

Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S . Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance. Leukemia. 2002; 16(2):170-7. DOI: 10.1038/sj.leu.2402341. View

Guo J, Si L, Kong Y, Flaherty K, Xu X, Zhu Y . Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011; 29(21):2904-9. DOI: 10.1200/JCO.2010.33.9275. View

Kruger S, Emig M, Lohse P, Ehninger G, Hochhaus A, Schackert H . The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians. Leukemia. 2005; 20(2):354-5. DOI: 10.1038/sj.leu.2404038. View

10.

Grabellus F, Worm K, Sheu S, Siffert W, Schmid K, Bachmann H . The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population. J Clin Pathol. 2011; 64(11):1021-4. DOI: 10.1136/jcp.2011.090498. View

11.

Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G . Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One. 2009; 4(11):e7746. PMC: 2768905. DOI: 10.1371/journal.pone.0007746. View

12.

Schirosi L, Nannini N, Nicoli D, Cavazza A, Valli R, Buti S . Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol. 2012; 23(9):2409-2414. DOI: 10.1093/annonc/mdr626. View

13.

Chugh R, Wathen J, Patel S, Maki R, Meyers P, Schuetze S . Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010; 16(19):4884-91. DOI: 10.1158/1078-0432.CCR-10-1177. View

14.

Bustin S, Beaulieu J, Huggett J, Jaggi R, Kibenge F, Olsvik P . MIQE précis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC Mol Biol. 2010; 11:74. PMC: 2955025. DOI: 10.1186/1471-2199-11-74. View

15.

Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G . High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004; 100(3):612-20. DOI: 10.1002/cncr.11937. View

16.

Seinfeld J, Kleinschmidt-DeMasters B, Tayal S, Lillehei K . Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status. J Neurosurg. 2006; 104(5):749-56. DOI: 10.3171/jns.2006.104.5.749. View

17.

Garbay D, Le Cesne A, Penel N, Chevreau C, Marec-Berard P, Blay J . Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol. 2011; 23(1):182-186. DOI: 10.1093/annonc/mdr051. View

18.

Heinrich M, Corless C, Demetri G, Blanke C, von Mehren M, Joensuu H . Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23):4342-9. DOI: 10.1200/JCO.2003.04.190. View

19.

Didelot A, Le Corre D, Luscan A, Cazes A, Pallier K, Emile J . Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol. 2012; 92(3):275-80. DOI: 10.1016/j.yexmp.2012.03.001. View

20.

Gounder M, Lefkowitz R, Keohan M, DAdamo D, Hameed M, Antonescu C . Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011; 17(12):4082-90. PMC: 3152981. DOI: 10.1158/1078-0432.CCR-10-3322. View